Collateral for a security interest recorded Sep 14, 2022 (Vickers Venture Fund VI Pte. Ltd.).
Term ends Aug 9, 2030 · High confidence
20-year base term ends Aug 9, 2030
Held by Biosplice Therapeutics, Inc.
Filed Jun 17, 2015 as application 14/741,645 · Granted Jul 5, 2016
Base term, 20 years from filing
Today
2010
2030
Clock starts
Aug 9, 2010
Aug 9, 2010
Term ends
Aug 9, 2030
Aug 9, 2030
Granted
Jul 5, 2016
Jul 5, 2016
base term
fee events
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 8,822,478, to Aug 9, 2030. The term already ends on or before that date, so the cap shortened nothing.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
8
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 2 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Aug 9, 2010, when application 12/852,706, the earliest non-provisional in its chain, was filed (this one was filed Jun 17, 2015) | Aug 9, 2030 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 8,822,478) | resolves to Aug 9, 2030, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Aug 9, 2030 | High confidence |
This family
| US 8,252,812 | In force Aug 2030 | Aug 2030 |
| US 8,822,478 | In force Sep 2030 | Sep 2030 |
| US 8,604,052 | Lapsed on the fee record Dec 2025 | Dec 2025 |
| US 8,703,794 | In force Aug 2030 | Aug 2030 |
| US 9,090,613 | In force Aug 2030 | Aug 2030 |
| US 9,381,192 | this patent Aug 2030 | Aug 2030 |
| US 9,763,927 | In force Aug 2030 | Aug 2030 |
| US 10,016,406 | Lapsed on the fee record Jul 2026 | Jul 2026 |
Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jul 9, 2015 Reel 36045, frame 844 | Hood, John; Wallace, David Mark; Kc, Sunil Kumar | Samumed, LLC | Assignment of Assignor's Interest |
| Mar 23, 2021 Reel 55693, frame 882 | Samumed, LLC | Biosplice Therapeutics, Inc. | Assignment of Assignor's Interest |
| Sep 14, 2022 reel/frame not recorded | Biosplice Therapeutics, Inc. | Vickers Venture Fund VI Pte. Ltd. | Security Interest |
| Sep 14, 2022 reel/frame not recorded | Biosplice Therapeutics, Inc. | Vickers Venture Fund VI (Plan) Pte. Ltd. | Security Interest |
| Sep 14, 2022 reel/frame not recorded | Biosplice Therapeutics, Inc. | Vickers-Splice Co.-Investment LLC | Security Interest |
| Sep 14, 2022 reel/frame not recorded | Biosplice Therapeutics, Inc. | Med-Pathways II Limited | Security Interest |
| Sep 14, 2022 Reel 61433, frame 786 | Biosplice Therapeutics, Inc. | Vickers Venture Fund VI Pte. Ltd.; Vickers Venture Fund VI (Plan) Pte. Ltd.; Vickers-Splice Co.-Investment LLC; Med-Pathways II Limited | Security Interest |
| Mar 12, 2026 Reel 75109, frame 434 | TMF Group New York, LLC, Not Individually But Solely as Collateral Agent | Biosplice Therapeutics, Inc. | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Aug 2030
Term ends Aug 9, 2030. Maintenance fees still fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 8,822,478, ends no earlier than this term, so it caps nothing.
Citations
51
later US patents cite this one
That is top 10% of utility patents granted in 2016 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.